Abstract
The conventional oncological approach was defined in the past as “one size fits all” and the tumors were treated according to the localization and the histopathological features. One of the future challenges in the field of oncology is the integration of translational research and technology innovation, in order to clarify unexplored aspects of the biology and the genetics of tumors, to develop a personalized treatment based on the molecular characteristics of the patient and his disease, that is the principle of precision medicine. New multidisciplinary teams are needed to ensure the integration of different professional profiles, including oncologists, pharmacologists, geneticians, and pathologists. In the new era of Precision Oncology, the nomenclature is fundamental, therefore we report here a glossary that might be useful to the clinical, basic, and applied research specialists.
AIOM (Associazione Italiana di Oncologia Medica) – SIAPEC (Società Italiana di Anatomia Patologica e Citologia Diagnostica) – SIBIOC (Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica) and SIF (Società Italiana di Farmacologia)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F. The European Society for Medical Oncology (ESMO) precision medicine glossary. Ann Oncol Jan. 2018;29(1):30–5.
Targeted Therapies for Solid Tumors. A handbook for moving toward new frontiers in cancer treatment, current clinical pathology. New York: Springer Science; 2015.
Davis AA, McKee AE, Kibbe WA, Villaflor VM. Complexity of delivering precision medicine: opportunities and challenges. Am Soc Clin Oncol Educ Book. 2018;23:998–1007.
Gruppo di Lavoro AIOM – SIAPEC-IAP – SIF – SIBioC: Raccomandazioni per l’esecuzione di test molecolari su biopsia liquida in oncologia, Luglio 2018. https://www.aiom.it/pubblicazioni/raccomandazioni-position-paper/raccomandazioni-perlesecuzione-di-test-molecolari-su-biopsia-liquida-in-oncologia-luglio-2018/.
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.
Russo A, Incorvaia L, Del Re M, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies [published online ahead of print, 2021 Jun 3]. ESMO Open. 2021;6(3):100164. https://doi.org/10.1016/j.esmoop.2021.100164.
Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526:361–70.
Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBIOC-SIF italian scientific societies [published online ahead of print, 2021 Aug 6]. Crit Rev Oncol Hematol. 2021;103436. https://doi.org/10.1016/j.critrevonc.2021.103436.
Capoluongo E, Salvatore F. https://www.agendadigitale.eu/sanita/medicina-di-precisione-epersonalizzata-le-nuove-sfide-del-sistema-sanitario/; 2018.
Oncologia di precisione 2018, Documento scientifico AIOM – SIAPEC – SIBIOC – SIF. www.aiom.it/wp-content/uploads/2018/11/2018_oncologia _di_precisione.pdf.
Kleppe M, Levine RL. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med. 2014;20:342–4.
Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, Davies H, Stratton MR, Campbell PJ. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029–41.
Weinstein IB. Cancer. Addiction to oncogenes–the Achilles heel of cancer. Science. 2002;297(5578):63–4.
Fanale D, Maragliano R, Bazan V, Russo A. Caretakers and gatekeepers, encyclopedia of life sciences: Wiley; 2017.
Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2016;23(8):1920–8.
Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;1:717–21.
Author information
Authors and Affiliations
Consortia
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
On behalf of the AIOM – SIAPEC – SIBIOC – SIF Working Group. et al. (2021). Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_28
Download citation
DOI: https://doi.org/10.1007/978-3-030-56051-5_28
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56050-8
Online ISBN: 978-3-030-56051-5
eBook Packages: MedicineMedicine (R0)